Hutchinson disease, formally called Hutchinson-Gilford progeria syndrome (HGPS), is an extremely rare genetic condition that causes children to age rapidly. It affects roughly 1 in 18 to 20 million people, with an estimated 410 to 483 children living with the condition worldwide as of late 2024. Children with progeria develop severe cardiovascular disease and have an average life expectancy of about 14.5 years.
The name comes from Jonathan Hutchinson and Hastings Gilford, two physicians who described the condition in the late 1800s. (Hutchinson’s name is also attached to several unrelated medical terms, including “Hutchinson’s triad,” a set of signs used to diagnose congenital syphilis, and “Hutchinson’s teeth,” a specific pattern of notched incisors. These are completely separate conditions.)
What Causes Progeria
Progeria is caused by a single-letter change in a gene called LMNA, which provides instructions for building a protein that supports the structural shell around each cell’s nucleus. The mutation activates an abnormal editing point in the gene, producing a shortened, defective version of the protein known as progerin. This defective protein accumulates over time and progressively distorts the nucleus of the cell, causing the nuclear envelope to become lobulated and thickened, disrupting the organization of DNA inside, and interfering with basic functions like cell division and DNA repair.
Because the nuclear shell plays a role in so many processes, including DNA replication and gene activity, the buildup of progerin essentially accelerates the wear and tear that cells normally accumulate over decades. Researchers have confirmed this directly: when the defective protein is introduced into healthy cells in the lab, it produces the same structural damage seen in progeria patients. Interestingly, small amounts of progerin also accumulate during normal aging, which is why studying progeria has become relevant to understanding how all of us age.
How Symptoms Develop
Babies with progeria typically look normal at birth. Within the first year or two of life, their growth rate slows dramatically, and they soon fall well behind other children their age in both height and weight. A distinctive appearance emerges: hair loss (often complete baldness), aged-looking skin, a pinched nose, and a small face and jaw that appear disproportionate to the head.
Intelligence and cognitive development are completely normal. The condition targets the body, not the brain. As children grow older, they develop problems more commonly seen in elderly adults: stiff joints, hip dislocations, and most critically, progressive cardiovascular disease. Despite looking like children, their arteries behave like those of someone decades older.
Why Cardiovascular Disease Is the Central Threat
The most dangerous feature of progeria is generalized atherosclerosis, the buildup of plaque and stiffening of artery walls that typically takes a lifetime to develop. In children with progeria, this process is dramatically accelerated. More than 80% of deaths result from heart failure, heart attack, or stroke, at an average age of 14.6 years.
What makes this especially striking is that these children lack the usual risk factors for heart disease. They don’t have elevated cholesterol or the inflammatory markers that normally drive plaque formation in adults. Instead, progerin directly damages the smooth muscle cells lining the artery walls, causing those cells to die off prematurely. This triggers a cascade of problems: the artery walls lose structural integrity, calcium deposits form, the vessel walls thicken with scar-like tissue, and cholesterol particles get trapped in the damaged tissue. The result is arteries that are stiff, narrowed, and prone to blockage, leading to heart attacks, strokes, and mini-strokes.
How It’s Diagnosed
Doctors may first suspect progeria based on the visible physical changes that appear in the first one to two years. A thorough evaluation includes tracking growth on standard charts, measuring blood pressure, and testing hearing and vision. The condition is confirmed through a genetic test that identifies the specific LMNA mutation. This test has been a significant advance, because it allows diagnosis earlier than was previously possible, when doctors had to rely entirely on physical signs that took time to fully develop. Earlier diagnosis means earlier access to treatment.
Treatment and Life Expectancy
In 2020, the FDA approved the first treatment specifically for progeria, a medication called Zokinvy (lonafarnib). It works by blocking one of the chemical steps that allows the defective progerin protein to attach to the nuclear membrane and cause damage. In clinical follow-up extending to 11 years, children treated with this medication lived an average of 2.5 years longer than untreated patients.
That gain is meaningful. According to Boston Children’s Hospital, long-term medical treatment has pushed average life expectancy from 14.5 years to nearly 20 years. Treatment doesn’t cure the disease, but it slows the progression of cardiovascular damage and gives children more time.
Supportive care addresses the day-to-day challenges of living with progeria. Joint stiffness and limited mobility are managed with physical therapy. Cardiovascular health is monitored closely, with attention to signs of artery disease. Nutrition support helps manage the growth and weight difficulties that are central to the condition.
Gene Editing as a Potential Cure
Because progeria is caused by a change to a single DNA letter, it is a strong candidate for a type of gene therapy called base editing. This approach uses CRISPR technology to find and correct the exact misspelling in the genetic code without cutting the DNA strand entirely. The Progeria Research Foundation reports that researchers have refined a base editing treatment and are now working on the steps needed to begin a clinical trial, including drug manufacturing, FDA engagement, and clinical trial design. If successful, this would represent a shift from slowing the disease to potentially correcting its root cause.